Scottish Medicines Consortium



Pegylated interferon alfa-2b (ViraferonPeg®) (No. 02/02) Schering-Plough

Summary of Recommendation

10 May 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in the NHS Scotland. The recommendation is summarised as follows:

ADVICE

Pegylated interferon alfa-2b is an appropriate treatment for the management of adult patients with chronic hepatitis C under the overall supervision of specialists experienced in the management of this disorder.

REASONS FOR ADVICE

This treatment involves a once weekly injection that reduces inconvenience to patients whilst increasing the response rate to both Pegylated interferon alfa-2b alone or in combination with Ribavirin.